SARS-CoV-2 nucleocapsid protein inhibits the PKR-mediated integrated stress response through RNA-binding domain N2b

PLoS Pathog. 2023 Aug 22;19(8):e1011582. doi: 10.1371/journal.ppat.1011582. eCollection 2023 Aug.

Abstract

The nucleocapsid protein N of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enwraps and condenses the viral genome for packaging but is also an antagonist of the innate antiviral defense. It suppresses the integrated stress response (ISR), purportedly by interacting with stress granule (SG) assembly factors G3BP1 and 2, and inhibits type I interferon responses. To elucidate its mode of action, we systematically deleted and over-expressed distinct regions and domains. We show that N via domain N2b blocks PKR-mediated ISR activation, as measured by suppression of ISR-induced translational arrest and SG formation. N2b mutations that prevent dsRNA binding abrogate these activities also when introduced in the intact N protein. Substitutions reported to block post-translation modifications of N or its interaction with G3BP1/2 did not have a detectable additive effect. In an encephalomyocarditis virus-based infection model, N2b - but not a derivative defective in RNA binding-prevented PKR activation, inhibited β-interferon expression and promoted virus replication. Apparently, SARS-CoV-2 N inhibits innate immunity by sequestering dsRNA to prevent activation of PKR and RIG-I-like receptors. Similar observations were made for the N protein of human coronavirus 229E, suggesting that this may be a general trait conserved among members of other orthocoronavirus (sub)genera.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19*
  • DNA Helicases
  • Encephalomyocarditis virus
  • Humans
  • Poly-ADP-Ribose Binding Proteins
  • RNA Helicases
  • RNA Recognition Motif Proteins / genetics
  • RNA-Binding Motifs
  • SARS-CoV-2* / genetics

Substances

  • DNA Helicases
  • Poly-ADP-Ribose Binding Proteins
  • RNA Helicases
  • RNA Recognition Motif Proteins
  • G3BP1 protein, human

Grants and funding

This work was supported by the European Union (Horizon 2020 Marie Skłodowska-Curie ETN “INITIATE”, grant agreement number 813343) to FJMvK and by the Dutch Research Council NWO OCENW.KLEIN.344 to FJMvK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.